Pertussis Market Overview: Current Landscape and Future Outlook
The Pertussis Market is poised for steady growth as global awareness of this highly contagious respiratory infection increases and more effective interventions are developed. Key players in the Pertussis Drugs Market include Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, and BioNet, among others. The market shows significant potential, especially with the introduction of innovative vaccines that target both children and adults.
Understanding Pertussis and Its Diagnosis
Pertussis, commonly known as whooping cough, is caused by Bordetella pertussis and progresses through three stages: catarrhal, paroxysmal, and convalescent. Accurate diagnosis is critical but challenging, relying on techniques such as culture, PCR, paired sera, and single sera tests, with paired sera tests considered the most reliable.
Prevention and Treatment
Vaccination remains the cornerstone of Pertussis Therapeutics Market strategies. In the U.S., DTaP and Tdap vaccines are widely used, with all adolescents and adults recommended to receive at least three doses. Treatment for infected individuals typically involves macrolide antibiotics, such as erythromycin, clarithromycin, or azithromycin, although side effects may affect adherence. Supportive care, including oxygen therapy, hydration, and avoiding respiratory irritants, also plays a vital role in patient recovery.
Epidemiology and Market Size
DelveInsight’s report, “Pertussis Market Insights, Epidemiology, and Market Forecast – 2034,” provides a comprehensive view of historical and projected epidemiology across major markets, including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. In 2022, approximately 19 million individuals were vaccinated in the U.S., with 5 million adults receiving booster doses. Across the seven major markets (7MM), around 34 million people were vaccinated, a number expected to rise over the forecast period due to updated immunization guidelines, new vaccines, and increased awareness. The Pertussis Treatment Market in the 7MM was valued at $3.5 billion in 2022, with the U.S. being the largest contributor.
Vaccine Landscape and Emerging Therapies
Current vaccines driving the Pertussis Therapeutics Market include:
ADACEL (Sanofi Pasteur): Trivalent booster for pertussis, tetanus, and diphtheria, available in 55 countries.
BOOSTRIX (GSK): Recommended for individuals aged 10 and above, including maternal immunization programs.
Emerging vaccines show promising potential:
BPZE1 (ILiAD Biotechnologies): An intranasal booster in Phase IIb, with FDA Fast Track designation.
BK1310/MT-2355 (Mitsubishi Tanabe Pharma): A 5-in-1 combination vaccine planned for launch in Japan in FY2023.
Market Outlook and Competitive Landscape
Complete immunization is critical for controlling pertussis. While infant and childhood vaccination rates are high, adult booster compliance remains relatively low. The Pertussis Companies operating in the U.S. and Europe face competitive dynamics with vaccines like PEDIARIX, PENTACEL, and Vaxelis, whereas Mitsubishi leads the Japanese market with TETRABIK.
The report also highlights adoption rates for newly launched and pipeline vaccines, patient uptake trends, sales performance, market share, collaborations, patent filings, and regulatory progress. Reimbursement scenarios and expert insights from key opinion leaders provide further clarity on economically attractive markets and unmet needs.
With increasing vaccine development, growing awareness, and robust Pertussis Market Size projections, stakeholders in the Pertussis Therapeutics Market are well-positioned to drive growth and innovation in this evolving healthcare landscape.
Latest Reports
Acute Pyelonephritis Market | Asperger Syndrome Market | Attention Deficit Hyperactivity Disorder Adhd Market | Cardiopulmonary Management Device Market | Childhood Atropine For Myopia Progression Market | Cholangiocarcinoma Market | Dyspepsia Market | Emphysema Market | Genital Herpes Market | Growth Hormone Deficiency Market | Guillain-barré Syndrome Market | Hairy Cell Leukemia Market | Intestinal Obstruction Market | Malignant Fibrous Histiocytoma Market | Menopause Market | Metabolic Acidosis Market | Multiple Myeloma Market | Neurostimulation Devices Market
